Navigation Links
Chimerix to Present at 9th Annual BIO Investor Forum
Date:9/28/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 28 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present a corporate overview at the upcoming BIO Investor Forum Conference on October 5th, 2010 at 2:00pm PT.  The conference is being held at the Palace Hotel in San Francisco, California.

Mr. Moch will discuss the company's antiviral pipeline and technology assets, including CMX001, a broad spectrum antiviral in clinical development for the treatment of double-stranded DNA viruses such as cytomegalovirus, adenovirus, BK virus, JC virus, Epstein-Barr virus and herpes simplex virus; and CMX157, being developed as a potential once-weekly nucleoside analogue against HIV infections.

The BIO Investor Forum is a conference for international investors focused on private and emerging public biotechnology companies.  In an effort to support industry-wide success, the conference presents a broad and unbiased view of investment opportunities with the support of physicians, scientists, and industry analysts.  

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  The company's lead candidate, CMX001, is in Phase 1 and Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, such as BK virus, cytomegalovirus and adenovirus.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies as a potent nucleoside analogue against multi-drug resistant HIV infections.  Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.  

Privately-held, Chimerix has received financing from Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
2. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
3. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
8. Delcath to Present at the William Blair Emerging Growth Stock Conference
9. China-Biotics to Present at Jefferies Healthcare Conference
10. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
11. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , Aug. 17, 2017 MJAC2017 , the ... Canna Broadcast Media, today reveals its leading lineup. ... Inc., a global cannabis innovator specializing in the development of ... the conference. MassRoots, Rambridge™ and The Green Organic Dutchman are ... and Namaste Vapes™ as silver sponsors. ...
(Date:8/15/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), is ... residents. Naloxone is available without ... retail pharmacy, G-3320 Beecher Road. ... Drug Administration, is intended to block or reverse the ... loss of consciousness. The medication is often carried by ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
Breaking Medicine Technology:
(Date:8/22/2017)... VEGAS, NEV. (PRWEB) , ... August 22, 2017 ... ... American Academy of Anti-Aging Medicine recently spoke at a popular international aesthetics conference ... therapy has had on restoring his patients’ health and his growing practice. , ...
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... 2017 , ... Nurses at Apple Rehab Watch Hill , a nursing ... and certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... Centers for Medicare and Medicaid Services, to have a CPI machine that will provide ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and ... named Edward Koontz. “To Walk Away” is the creation of published author, Larry R. ... two hundred manuscripts in chemistry and religion, as well as four novels. , ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... heart-wrenching story of child abuse and neglect, and the struggles faced while hoping ... is the creation of published author, Judy Von Bernewitz, who spent 13 years ...
Breaking Medicine News(10 mins):